Aura Biosciences Inc. (AURA)
Aura Biosciences Statistics
Share Statistics
Aura Biosciences has 49.95M shares outstanding. The number of shares has increased by 0.9% in one year.
| Shares Outstanding | 49.95M |
| Shares Change (YoY) | 0.9% |
| Shares Change (QoQ) | 0.7% |
| Owned by Institutions (%) | 74.23% |
| Shares Floating | 44.45M |
| Failed to Deliver (FTD) Shares | 1.34K |
| FTD / Avg. Volume | 0.86% |
Short Selling Information
The latest short interest is 1.41M, so 2.82% of the outstanding shares have been sold short.
| Short Interest | 1.41M |
| Short % of Shares Out | 2.82% |
| Short % of Float | 3.14% |
| Short Ratio (days to cover) | 8.26 |
Valuation Ratios
The PE ratio is -4.59 and the forward PE ratio is -3.87. Aura Biosciences's PEG ratio is -4.39.
| PE Ratio | -4.59 |
| Forward PE | -3.87 |
| PS Ratio | 0 |
| Forward PS | 3.3 |
| PB Ratio | 1.55 |
| P/FCF Ratio | -5.44 |
| PEG Ratio | -4.39 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aura Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.76, with a Debt / Equity ratio of 0.09.
| Current Ratio | 18.76 |
| Quick Ratio | 18.76 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 7.97 |
| Cash Flow / Debt | -3.26 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -34.7%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -34.7% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-868,272.73 |
| Employee Count | 88 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 137K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -19.8% in the last 52 weeks. The beta is 0.29, so Aura Biosciences's price volatility has been higher than the market average.
| Beta | 0.29 |
| 52-Week Price Change | -19.8% |
| 50-Day Moving Average | 7.89 |
| 200-Day Moving Average | 8.47 |
| Relative Strength Index (RSI) | 36.45 |
| Average Volume (20 Days) | 156.14K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.29M |
| Operating Income | -84.99M |
| Net Income | -76.41M |
| EBITDA | -83.7M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.93 |
Balance Sheet
The company has 41.06M in cash and 19.56M in debt, giving a net cash position of 21.51M.
| Cash & Cash Equivalents | 41.06M |
| Total Debt | 19.56M |
| Net Cash | 21.51M |
| Retained Earnings | -287.31M |
| Total Assets | 205.34M |
| Working Capital | 168.77M |
Cash Flow
In the last 12 months, operating cash flow was -63.85M and capital expenditures -709K, giving a free cash flow of -64.56M.
| Operating Cash Flow | -63.85M |
| Capital Expenditures | -709K |
| Free Cash Flow | -64.56M |
| FCF Per Share | -1.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -26.77% |
| FCF Yield | -17.91% |
Analyst Forecast
The average price target for AURA is $23, which is 219% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 219% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 4.24 |
| Piotroski F-Score | 2 |